Akamis Bio, a clinical-stage oncology company using a proprietary Tumor-Specific Immuno-Gene (T-SIGn®) therapy platform to deliver novel immunotherapeutic proteins, biomolecules and transgene combinations to treat solid tumors, today announced $60 million in funding linked to the close of a Series A Prime financing round and entry into a strategic partnership for the development of its lead clinical candidate, NG-350A.The Series A Prime financing was led by Sedgwick Yard, a global biotech venture capital firm with Greater China roots.

Akamis Bio是一家临床阶段肿瘤公司，使用专有的肿瘤特异性免疫基因（T-SIGn®）治疗平台提供新型免疫治疗蛋白，生物分子和转基因组合来治疗实体瘤，今天宣布6000万美元的资金与a系列主要融资回合的结束有关，并为其主要临床候选人NG-350A的开发建立了战略合作伙伴关系。A系列主要融资由Sedgwick Yard牵头，这是一家总部位于大中华区的全球生物技术风险投资公司。

In a separate transaction, Akamis Bio entered into a licensing agreement granting Xuanzhu Biopharma the Greater China Region Rights to NG-350A. Akamis Bio is a clinical-stage oncology company using a proprietary Tumor-Specific Immuno-Gene Therapy (T-SIGn®) platform to deliver novel immunotherapeutic proteins, biomolecules and transgene combinations to treat solid tumors.

在另一笔交易中，Akamis Bio签署了一份许可协议，授予Xuanzhu Biopharma NG-350A在大中华区的权利。Akamis Bio是一家临床阶段肿瘤公司，使用专有的肿瘤特异性免疫基因治疗（T-SIGn®）平台提供新型免疫治疗蛋白，生物分子和转基因组合来治疗实体瘤。

The company is developing a portfolio of solid tumor-targeted T-SIGn therapeutics which aim to enable a patient's own immune system to recognize, attack, and clear their cancer. Akamis Bio has a growing pipeline of T-SIGn therapeutics anchored by its lead clinical-stage program, NG-350A (an immuno-stimulatory tumor gene therapy driving intratumoral expression of a CD40 agonist monoclonal antibody) being investigated in ongoing Phase 1 clinical studies in patients with metastatic or advanced epithelial tumors.

该公司正在开发一系列针对实体瘤的T-SIGn疗法，旨在使患者自身的免疫系统能够识别，攻击和清除癌症。Akamis Bio的主要临床阶段计划NG-350A（一种驱动CD40激动剂单克隆抗体肿瘤内表达的免疫刺激性肿瘤基因疗法）正在进行转移性或晚期上皮性肿瘤患者的1期临床研究中，正在研究越来越多的T-SIGn治疗剂。

In addition to internal pipeline development efforts, Akamis Bio has a number of T-SIGn platform-focused collaborations with leaders in the immuno-oncology field including Merck and the Cancer Research Institute (CRI)..

除了内部管道开发工作外，Akamis Bio还与包括默克（Merck）和癌症研究所（CRI）在内的免疫肿瘤学领域的领导者进行了许多以T-SIGn平台为重点的合作。